[Alpha Biz= Kim Jisun] On April 7, ABL Bio, a company listed on the KOSDAQ market, announced that it has transferred its drug development platform, 'Grabody-B', to the British pharmaceutical company GlaxoSmithKline (GSK).



ABL will receive a total of up to 4.1 trillion Korean won, including an upfront payment and short-term milestones (stage-based royalties) amounting to 148 billion Korean won. This deal is the second-largest technology export by a domestic bio company, following Alteogen's 4.7 trillion Korean won deal in 2020.



Grabody-B is a drug development platform designed to help drugs cross the blood-brain barrier (BBB). ABL Bio and GSK will use Grabody-B to develop treatments for degenerative brain diseases, including Alzheimer's.

 

 

 

[ⓒ AlphaBIZ. 무단전재-재배포 금지]